JOHN BURKINS: Open Payments
NPI 1811971864 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,210 in 60 payments from 9 companies in 2025. Trend: 2023 $987 · 2024 $1,113 · 2025 $2,210
Food & beverage: $2,092Education: $118
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $693 |
| Neurocrine BioSciences, Inc. | 12 | $376 |
| Janssen Pharmaceuticals, Inc | 9 | $300 |
| E.R. Squibb & Sons, L.L.C. | 6 | $229 |
| Vanda Pharmaceuticals Inc. | 4 | $189 |
| ABBVIE INC. | 2 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $113 |
| Alkermes, Inc. | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
Products named: UZEDY, INGREZZA, INVEGA SUSTENNA, COBENFY, AUSTEDO XR, FANAPT, VRAYLAR, CAPLYTA.
Industry payments across PA — which companies pay providers there.
